文献速递骨软组织肉瘤与黑色素瘤

COLUMBUS 7年更新:恩科拉非尼联合比美替尼对比维莫非尼或恩科拉非尼单药治疗BRAF V600E/K突变黑色素瘤的随机开放标签III期试验

COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanoma.
PubMed 文献 · Eur J Cancer · 2024-04-24

COLUMBUS part 1研究7年分析纳入577例BRAF V600E/K突变晚期黑色素瘤患者,按1:1:1随机接受恩科拉非尼联合比美替尼、维莫非尼或恩科拉非尼单药治疗。中位随机化至数据截止时间99.7个月时,联合组7年PFS率和OS率分别为21.2%和27.4%,维莫非尼组分别为6.4%和18.2%;联合组中位黑色素瘤特异性生存36.8个月,维莫非尼组19.3个月。安全性结果与已知特征一致。

要点

  • 恩科拉非尼联合比美替尼组7年PFS率21.2%(95%CI 14.7-28.4%),维莫非尼组6.4%(95%CI 2.1-14.0%)。
  • 联合组7年OS率27.4%(95%CI 21.2-33.9%),维莫非尼组18.2%(95%CI 12.8-24.3%)。
  • 联合组中位黑色素瘤特异性生存36.8个月(95%CI 27.7-51.5个月),维莫非尼组19.3个月(95%CI 14.8-25.9个月)。

核心结论

  • 这是BRAF/MEK抑制剂联合方案治疗BRAF V600E/K突变转移性黑色素瘤III期试验中最长的随访结果,支持恩科拉非尼联合比美替尼在该人群中的长期疗效和已知安全性,并提供长期应答者的新见解。

研究设计与样本

  • COLUMBUS part 1(NCT01909453)随机、开放标签、III期试验的7年分析,中位随机化至数据截止时间99.7个月。
  • 纳入577例局部晚期不可切除或转移性BRAF V600E/K突变黑色素瘤患者,为初治或一线免疫治疗后进展,不允许既往BRAF/MEK抑制剂治疗。
  • 患者按1:1:1随机接受恩科拉非尼450 mg每日一次联合比美替尼45 mg每日两次(n=192)、维莫非尼960 mg每日两次(n=191)或恩科拉非尼单药300 mg每日一次(n=194)。

主要发现

  • 7年PFS率(95%CI)在恩科拉非尼联合比美替尼组为21.2%(14.7-28.4%),维莫非尼组为6.4%(2.1-14.0%)。
  • 7年OS率(95%CI)在恩科拉非尼联合比美替尼组为27.4%(21.2-33.9%),维莫非尼组为18.2%(12.8-24.3%)。
  • 中位黑色素瘤特异性生存(95%CI)在恩科拉非尼联合比美替尼组为36.8个月(27.7-51.5个月),维莫非尼组为19.3个月(14.8-25.9个月)。
  • 在各治疗组中共识别出34例长期应答者(7年时完全/部分缓解持续)。
  • 安全性结果与恩科拉非尼联合比美替尼已知的耐受性特征一致。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Treatment with encorafenib plus binimetinib and encorafenib monotherapy is associated with improved progression-free survival (PFS) and overall survival (OS) compared with vemurafenib in patients with BRAF V600E/K-mutant metastatic melanoma. We report results from the 7-year analysis of COLUMBUS part 1 (NCT01909453) at 99.7 months (median duration between randomization and data cutoff). METHODS: 577 patients with locally advanced unresectable or metastatic BRAF V600E/K-mutant melanoma who were treatment-naive or progressed after first-line immunotherapy were randomized 1:1:1 to encorafenib 450 mg once daily (QD) plus binimetinib 45 mg twice daily (BID) (n = 192), vemurafenib 960 mg BID (n = 191), or encorafenib monotherapy 300 mg QD (n = 194). No prior BRAF/MEK inhibitor was allowed. RESULTS: Seven-year PFS and OS rates (95 % CI) were 21.2 % (14.7-28.4 %) and 27.4 % (21.2-33.9%) in the encorafenib plus binimetinib arm and 6.4 % (2.1-14.0 %) and 18.2 % (12.8-24.3 %) in the vemurafenib arm, respectively. Median melanoma-specific survival (95 % CI) was 36.8 months (27.7-51.5 months) in the encorafenib plus binimetinib arm and 19.3 months (14.8-25.9 months) in the vemurafenib arm. Thirty-four long-term responders (complete/partial response ongoing at 7 years) were identified across arms. CONCLUSIONS: This is the longest follow-up from a phase III trial of BRAF/MEK inhibitor combination in BRAF V600E/K-mutant metastatic melanoma. Safety results were consistent with the known tolerability profile of encorafenib plus binimetinib. Results support the long-term efficacy and known safety of encorafenib plus binimetinib in this population and provide new insights on long-term responders. Interactive data visualization is available at the COLUMBUS dashboard (https://clinical-trials.dimensions.ai/columbus7/).

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Schadendorf D, Dummer R, Flaherty KT, et al. COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanoma. Eur J Cancer. 2024. PMID: 38723373. doi:10.1016/j.ejca.2024.114073

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。